Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer.

BACKGROUND

Accumulating evidence indicates tumor-promoting roles of synaptotagmin 13 () in several cancers; however, no studies have investigated its expression in breast cancer (BC). This study aimed to clarify the significance of in BC.

METHODS

mRNA expression levels were evaluated in BC cell lines. Polymerase chain reaction (PCR) array analysis was conducted to determine the correlation between expression levels of and other tumor-associated genes. Then, the association of expression levels in the clinical BC specimens with patients' clinicopathological factors was evaluated. These findings were subsequently validated using The Cancer Genome Atlas (TCGA) database.

RESULTS

Among 13 BC cell lines, estrogen receptor (ER)-positive cells showed higher mRNA levels than ER-negative cells. PCR array analysis revealed positive correlations between and several oncogenes predominantly expressed in ER-positive BC, such as , , and . In 165 patients, ER-positive specimens exhibited higher mRNA expression levels than ER-negative specimens. The TCGA database analysis confirmed that patients with ER-positive BC expressed higher levels than ER-negative patients.

CONCLUSION

This study suggests that is highly expressed in ER-positive BC cells and clinical specimens, and there is a positive association of with the ER signaling pathways.